253 related articles for article (PubMed ID: 23431365)
1. Apigenin sensitizes prostate cancer cells to Apo2L/TRAIL by targeting adenine nucleotide translocase-2.
Oishi M; Iizumi Y; Taniguchi T; Goi W; Miki T; Sakai T
PLoS One; 2013; 8(2):e55922. PubMed ID: 23431365
[TBL] [Abstract][Full Text] [Related]
2. Short-hairpin RNA-induced suppression of adenine nucleotide translocase-2 in breast cancer cells restores their susceptibility to TRAIL-induced apoptosis by activating JNK and modulating TRAIL receptor expression.
Jang JY; Jeon YK; Choi Y; Kim CW
Mol Cancer; 2010 Sep; 9():262. PubMed ID: 20875141
[TBL] [Abstract][Full Text] [Related]
3. Dihydroartemisinin enhances Apo2L/TRAIL-mediated apoptosis in pancreatic cancer cells via ROS-mediated up-regulation of death receptor 5.
Kong R; Jia G; Cheng ZX; Wang YW; Mu M; Wang SJ; Pan SH; Gao Y; Jiang HC; Dong DL; Sun B
PLoS One; 2012; 7(5):e37222. PubMed ID: 22666346
[TBL] [Abstract][Full Text] [Related]
4. Cardiac glycosides initiate Apo2L/TRAIL-induced apoptosis in non-small cell lung cancer cells by up-regulation of death receptors 4 and 5.
Frese S; Frese-Schaper M; Andres AC; Miescher D; Zumkehr B; Schmid RA
Cancer Res; 2006 Jun; 66(11):5867-74. PubMed ID: 16740726
[TBL] [Abstract][Full Text] [Related]
5. Proteasome inhibitor MG132 upregulates death receptor 5 and cooperates with Apo2L/TRAIL to induce apoptosis in Bax-proficient and -deficient cells.
He Q; Huang Y; Sheikh MS
Oncogene; 2004 Apr; 23(14):2554-8. PubMed ID: 14691451
[TBL] [Abstract][Full Text] [Related]
6. Tunicamycin enhances tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis in human prostate cancer cells.
Shiraishi T; Yoshida T; Nakata S; Horinaka M; Wakada M; Mizutani Y; Miki T; Sakai T
Cancer Res; 2005 Jul; 65(14):6364-70. PubMed ID: 16024639
[TBL] [Abstract][Full Text] [Related]
7. Wogonin and related natural flavones overcome tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) protein resistance of tumors by down-regulation of c-FLIP protein and up-regulation of TRAIL receptor 2 expression.
Ding J; Polier G; Köhler R; Giaisi M; Krammer PH; Li-Weber M
J Biol Chem; 2012 Jan; 287(1):641-649. PubMed ID: 22086925
[TBL] [Abstract][Full Text] [Related]
8. Anti-gout agent allopurinol exerts cytotoxicity to human hormone-refractory prostate cancer cells in combination with tumor necrosis factor-related apoptosis-inducing ligand.
Yasuda T; Yoshida T; Goda AE; Horinaka M; Yano K; Shiraishi T; Wakada M; Mizutani Y; Miki T; Sakai T
Mol Cancer Res; 2008 Dec; 6(12):1852-60. PubMed ID: 19074830
[TBL] [Abstract][Full Text] [Related]
9. Apo2L/TRAIL differentially modulates the apoptotic effects of sulindac and a COX-2 selective non-steroidal anti-inflammatory agent in Bax-deficient cells.
He Q; Luo X; Huang Y; Sheikh MS
Oncogene; 2002 Sep; 21(39):6032-40. PubMed ID: 12203115
[TBL] [Abstract][Full Text] [Related]
10. The dietary flavonoid apigenin sensitizes malignant tumor cells to tumor necrosis factor-related apoptosis-inducing ligand.
Horinaka M; Yoshida T; Shiraishi T; Nakata S; Wakada M; Sakai T
Mol Cancer Ther; 2006 Apr; 5(4):945-51. PubMed ID: 16648565
[TBL] [Abstract][Full Text] [Related]
11. Sorafenib sensitizes solid tumors to Apo2L/TRAIL and Apo2L/TRAIL receptor agonist antibodies by the Jak2-Stat3-Mcl1 axis.
Abdulghani J; Allen JE; Dicker DT; Liu YY; Goldenberg D; Smith CD; Humphreys R; El-Deiry WS
PLoS One; 2013; 8(9):e75414. PubMed ID: 24086526
[TBL] [Abstract][Full Text] [Related]
12. Sub-toxic dose of apigenin sensitizes HepG2 cells to TRAIL through ERK-dependent up-regulation of TRAIL receptor DR5.
Kim EY; Yu JS; Yang M; Kim AK
Mol Cells; 2013 Jan; 35(1):32-40. PubMed ID: 23224239
[TBL] [Abstract][Full Text] [Related]
13. Tunicamycin sensitizes human prostate cells to TRAIL-induced apoptosis by upregulation of TRAIL receptors and downregulation of cIAP2.
Jung YH; Lim EJ; Heo J; Kwon TK; Kim YH
Int J Oncol; 2012 Jun; 40(6):1941-8. PubMed ID: 22426894
[TBL] [Abstract][Full Text] [Related]
14. Mechanisms of resistance of human glioma cells to Apo2 ligand/TNF-related apoptosis-inducing ligand.
Rieger J; Frank B; Weller M; Wick W
Cell Physiol Biochem; 2007; 20(1-4):23-34. PubMed ID: 17595512
[TBL] [Abstract][Full Text] [Related]
15. A novel, soluble compound, C25, sensitizes to TRAIL-induced apoptosis through upregulation of DR5 expression.
James MA; Seibel WL; Kupert E; Hu XX; Potharla VY; Anderson MW
Anticancer Drugs; 2015 Jun; 26(5):518-30. PubMed ID: 25646742
[TBL] [Abstract][Full Text] [Related]
16. Oxidative stress-driven DR5 upregulation restores TRAIL/Apo2L sensitivity induced by iron oxide nanoparticles in colorectal cancer.
Shi Y; Wang J; Liu J; Lin G; Xie F; Pang X; Pei Y; Cheng Y; Zhang Y; Lin Z; Yin Z; Wang X; Niu G; Chen X; Liu G
Biomaterials; 2020 Mar; 233():119753. PubMed ID: 31923762
[TBL] [Abstract][Full Text] [Related]
17. Valproic acid sensitizes K562 erythroleukemia cells to TRAIL/Apo2L-induced apoptosis.
Iacomino G; Medici MC; Russo GL
Anticancer Res; 2008; 28(2A):855-64. PubMed ID: 18507029
[TBL] [Abstract][Full Text] [Related]
18. Membrane expression of DR4, DR5 and caspase-8 levels, but not Mcl-1, determine sensitivity of human myeloma cells to Apo2L/TRAIL.
Gómez-Benito M; Martinez-Lorenzo MJ; Anel A; Marzo I; Naval J
Exp Cell Res; 2007 Jul; 313(11):2378-88. PubMed ID: 17462628
[TBL] [Abstract][Full Text] [Related]
19. Apigenin potentiates TRAIL therapy of non-small cell lung cancer via upregulating DR4/DR5 expression in a p53-dependent manner.
Chen M; Wang X; Zha D; Cai F; Zhang W; He Y; Huang Q; Zhuang H; Hua ZC
Sci Rep; 2016 Oct; 6():35468. PubMed ID: 27752089
[TBL] [Abstract][Full Text] [Related]
20. Apoptosis induction in prostate cancer cells and xenografts by combined treatment with Apo2 ligand/tumor necrosis factor-related apoptosis-inducing ligand and CPT-11.
Ray S; Almasan A
Cancer Res; 2003 Aug; 63(15):4713-23. PubMed ID: 12907654
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
